Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ACER

Acer Therapeutics (ACER) Stock Price, News & Analysis

Acer Therapeutics logo

About Acer Therapeutics Stock (NASDAQ:ACER)

Key Stats

Today's Range
$0.66
$0.85
50-Day Range
$0.66
$0.90
52-Week Range
$0.55
$4.56
Volume
574,600 shs
Average Volume
N/A
Market Capitalization
$16.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Receive ACER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACER Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Anumana Appoints Harry S. Palmin as CFO
See More Headlines

ACER Stock Analysis - Frequently Asked Questions

Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings data on Friday, November, 19th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05.

The following companies are subsidiaries of Acer Therapeutics: Opexa Therapeutics Inc..

Based on aggregate information from My MarketBeat watchlists, some other companies that Acer Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Adobe (ADBE) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
11/19/2021
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ACER
Employees
30
Year Founded
2013

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.26 million
Book Value
($1.05) per share

Miscellaneous

Free Float
19,963,000
Market Cap
$16.15 million
Optionable
Not Optionable
Beta
N/A

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ACER) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners